Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

RedHill Biopharma (RDHL) EBITDA (2016 - 2023)

RedHill Biopharma has reported EBITDA over the past 12 years, most recently at $53.8 million for Q2 2023.

  • Quarterly EBITDA rose 358.99% to $53.8 million in Q2 2023 from the year-ago period, while the trailing twelve-month figure was -$15.4 million through Jun 2023, up 83.18% year-over-year, with the annual reading at -$7.9 million for FY2025, 34.91% down from the prior year.
  • EBITDA was $53.8 million for Q2 2023 at RedHill Biopharma, up from -$29.1 million in the prior quarter.
  • Over five years, EBITDA peaked at $53.8 million in Q2 2023 and troughed at -$141.6 million in Q4 2021.
  • The 5-year median for EBITDA is $16.6 million (2020), against an average of $3.3 million.
  • Year-over-year, EBITDA crashed 818.34% in 2021 and then surged 358.99% in 2023.
  • A 5-year view of EBITDA shows it stood at $11.8 million in 2019, then surged by 67.53% to $19.7 million in 2020, then crashed by 818.34% to -$141.6 million in 2021, then soared by 46.5% to -$75.7 million in 2022, then surged by 170.97% to $53.8 million in 2023.
  • Per Business Quant, the three most recent readings for RDHL's EBITDA are $53.8 million (Q2 2023), -$29.1 million (Q1 2023), and -$75.7 million (Q4 2022).